Intellia Therapeutics, Inc.
NASDAQ:NTLABiotechnology
+$0.02 today
- Market cap
- $1.34B
- Beta
- 1.81
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$3.33
Volume 9.96M
Average 6.11M
Balance Sheet
Inspect the capital base behind the business.
Assets
$842.13M
FY 2025 · Annual
-29.3% YoYLiabilities
$170.73M
FY 2025 · Annual
-46.5% YoYEquity
$671.39M
FY 2025 · Annual
-23.0% YoYBalance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 123.41M | 523.51M | 226.75M | 189.18M | 155.46M |
| Short-term Investments | 625.28M | 669.12M | 685.48M | 412.33M | 294.42M |
| Net Receivables | 2.03M | 3.77M | 36.46M | 8.52M | 9.47M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 20.41M | 49.65M | 29.83M | 68.36M |
| Total Current Assets | 769.3M | 1.22B | 998.33M | 639.86M | 527.71M |
| Property, Plant & Equipment (Net) | 100.11M | 161M | 148.14M | 246.67M | 123.63M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 425.05M | 142.32M | 154.51M | 44.26M | 35.54M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 260.22M | 155.25M |
| Total Non-current Assets | 525.16M | 303.32M | 302.65M | 551.15M | 314.42M |
| Total Assets | 1.29B | 1.52B | 1.3B | 1.19B | 842.13M |
| Account Payables | 9.65M | 5.15M | 7.45M | 14.59M | 20.25M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 63.76M | 43.84M | 22.14M | 20.66M | 7.29M |
| Other Current Liabilities | 20.36M | 21.78M | 6.89M | 24.08M | 23.07M |
| Total Current Liabilities | 125.83M | 126.55M | 115.21M | 110.85M | 103.88M |
| Long-term Debt | 0 | 0 | 0 | 0 | 66.85M |
| Deferred Tax Liabilities | 0 | 0 | (38.85M) | 0 | 0 |
| Deferred Revenue (Non-current) | 63.48M | 19.93M | 38.85M | 18.26M | 0 |
| Other Non-current Liabilities | 0 | 24.03M | 38.85M | 0 | 0 |
| Total Non-current Liabilities | 128.39M | 157.98M | 135.6M | 208.21M | 66.85M |
| Total Liabilities | 254.22M | 284.53M | 250.81M | 319.06M | 170.73M |
| Common Stock | 7K | 9K | 9K | 10K | 12K |
| Retained Earnings | (703M) | (1.18B) | (1.66B) | (2.18B) | (2.59B) |
| Accumulated OCI | (2.63M) | (7.46M) | (2.26M) | 605K | 1.03M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 1.04B | 1.24B | 1.05B | 871.96M | 671.39M |
| Total Debt | 74.02M | 130.7M | 115.35M | 210.2M | 93.33M |
| Net Debt | (49.38M) | (392.8M) | (111.4M) | 21.02M | (62.14M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $134.7M |
| Short-term Investments | $241.3M |
| Receivables | $9.1M |
| Other Current | $81.3M |
| Total Current Assets | $466.4M |
| PP&E (Net) | $113.1M |
| Long-term Investments | $38.0M |
| Other Non-current | $141.3M |
| Total Non-current Assets | $292.3M |
| Total Assets | $758.8M |
Analysis
Selected assets total $758.8M for Latest. The largest visible component is Short-term Investments at $241.3M, about 31.8% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K/A | 8-K/A filing | Nov 13, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 |
How much cash does NTLA have?
Intellia Therapeutics, Inc. (NTLA) reported $155.46M in cash and equivalents in fiscal 2025.
How much debt does NTLA carry?
Intellia Therapeutics, Inc. (NTLA) reported $93.33M of total debt, with net debt of -$62.13M.
Continue the stock analysis
Jump to another research area for this company.